ClinicalTrials.gg
CompletedNCT03598790BE BRIGHTUpdated Apr 15, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Bimekizumab in Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 189 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
Largest of 20
1,353 · median 161
Started
2018
with 3 others
Phase 3
10 of 20
2 open now
Registered
9th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one has the largest enrollment, is one of 4 that started in 2018, is one of 10 in phase 3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Read the detailed description

The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Bimekizumab
  • PSO
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Treatment Period (open-label)

  • Subject is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication intake according to the judgment of the Investigator
  • Subject completes the feeder study (PS0008 [NCT03412747], PS0009 [NCT03370133], PS0013 [NCT03410992]) without meeting any withdrawal criteria
  • Female subjects must be:

    1. : Menopause is defined as 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause
    2. Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)
    3. Or, if of (and engaged in sexual activity that could result in procreation), must be willing to use a highly effective method of throughout the duration of the study until 20 weeks after last administration of medicinal product (IMP), and have a negative pregnancy test at the feeder study in final visit/Baseline visit in PS0014

OLE2 Period (USA and Canada)

  • Completed the OLE Period without meeting any withdrawal criteria
  • Compliant with ongoing clinical study requirements
  • Female subject of childbearing potential must be willing to use highly effective method of contraception
  • Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)
  • Signed a separate OLE2 Period ICF

Exclusion criteria

Exclusion Criteria:

Treatment Period (open-label)

  • Subject has previously participated in this study
  • Female subjects who plan to become pregnant during the study or within 20 weeks following last dose of study medication
  • Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study. Note: For any subject with an ongoing Serious Adverse Event (SAE), or a history of serious infections in the feeder study, the Medical Monitor must be consulted prior to the subject's entry into PS0014, although the decision on whether to enroll the subject remains with the Investigator
  • Subject has a positive or indeterminate interferon gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
  • Subject may not participate in another study of a medicinal product or device under investigation other than the substudy
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Baseline as assessed by medical history, site interview, and/or results of the specified urine drug screen

OLE2 Period (USA and Canada)

  • Subject has developed any medical or psychiatric condition, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in OLE2 Period
  • Subject had a positive or indeterminate interferon-gamma release assay (IGRA) in the OLE study to Week 144, unless appropriately evaluated and treated
  • Presence of active suicidal ideation or severe depression
  • Subject has developed any active or history of malignancy prior to the OLE2 Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,353 participants (actual)

Study arms

  • Experimental
    Bimekizumab dose regimen 1

    Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48) Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks. Intervention Name: Bimekizumab

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dose regimen 2

    Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label). Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2. Intervention Name: Bimekizumab

    Drug: Bimekizumab

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: UCB4940

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)

    The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period

Secondary outcomes

  1. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP

    The number of SAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk is used.

    Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period

  2. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP

    The number of TEAEs leading to withdrawal adjusted by duration of exposure to study treatment were scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period

  3. Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)

    The PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B

  4. Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)

    PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum score is 0= no disease, maximum score is 72= maximal disease.

    Time frame: Week 144 compared to Baseline of PS0014 for Cohort B

  5. Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)

    The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of clear \[0\] or almost clear \[1\] with at least two category improvement from Baseline at visit timepoint.

    Time frame: Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B

  6. Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)

    The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of 0 or 1 at Week 144.

    Time frame: Week 144 for Cohort B EP and GPP groups

07

Results

Posted Dec 6, 2024

Participant flow

The study started to enroll participants in September 2018 and concluded in November 2023. Participant flow refers to the Cohort A Safety Set, Cohort A OLE2 Period Set and Cohort B Safety Set. Participants who enrolled in PS0014 after completion of Phase 3 feeder studies were included in Cohort A. An additional Cohort B was added in Japan.

Treatment Period (TP): Wk0-Wk144
Participant flow — Treatment Period (TP): Wk0-Wk144
MilestoneCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Started38483370000451110
Completed326746000038108
Not completed588770000712
Withdrew: Adverse event243324000312
Withdrew: Lack of efficacy475000200
Withdrew: Protocol violation124000000
Withdrew: Lost to follow-up71114000000
Withdrew: Consent withdrawn by subject142617000100
Withdrew: Pregnancy100000000
Withdrew: Covid-19 pandemic circumstances010000000
Withdrew: Physician decision001000000
Withdrew: Long ip pause; investigator decided termination100000000
Withdrew: Withdrawn by sponsor100000000
Withdrew: Patient did not comply with safety precautions100000000
Withdrew: Covid-19 pandemic circumstances021000000
Withdrew: Sponsor's decision120000000
Withdrew: Unplanned elective surgery010000000
Withdrew: Non-compliance010000000
Withdrew: Site closure; subject did not want to transfer001000000
Withdrew: Covid-19 restrictions; subject unable to return001000000
Withdrew: Subject withdraw consent (fear of another ae)001000000
Withdrew: The subject can't visit the hospital anymore000000100
Withdrew: Completed treatment but missed week 144 visit310000000
Withdrew: Non-compliance-pi early terminated the subject001000000
OLE2 Period: Wk 144/OLE2 BL- OLE2 Wk 48
Participant flow — OLE2 Period: Wk 144/OLE2 BL- OLE2 Wk 48
MilestoneCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Started0002265141000
Completed0002164939000
Not completed0001022000
Withdrew: Adverse event000212000
Withdrew: Lack of efficacy000200000
Withdrew: Lost to follow-up000400000
Withdrew: Consent withdrawn000110000
Withdrew: Pt cannot commit to study schedule000100000

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)

The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)
no. of new events per 100 subject-yearsCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)97.83 (91.73 to 104.22)179.68 (166.62 to 193.49)79.02 (65.97 to 93.89)77.11 (51.64 to 110.74)73.78 (47.75 to 108.92)244.08 (178.03 to 326.60)328.25 (163.86 to 587.33)188.71 (86.29 to 358.22)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP

The number of SAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk is used.

Time frame:
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP
no. of new events per 100 subject-yearsCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP5.24 (4.36 to 6.25)6.72 (5.19 to 8.56)4.44 (2.22 to 7.95)9.05 (2.94 to 21.13)8.93 (2.43 to 22.86)5.86 (2.36 to 12.08)19.51 (6.34 to 45.54)7.56 (0.92 to 27.32)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP

The number of TEAEs leading to withdrawal adjusted by duration of exposure to study treatment were scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP
no. of new events per 100 subject-yearsCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP2.11 (1.57 to 2.76)2.59 (1.69 to 3.80)0.79 (0.10 to 2.86)1.77 (0.04 to 9.86)4.37 (0.53 to 15.79)2.42 (0.50 to 7.08)3.27 (0.08 to 18.19)7.68 (0.93 to 27.74)
SecondaryPsoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)

The PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Reported as:
Number · percentage of participants
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)
percentage of participantsCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320mg Q4WCohort B: PSO BKZ Total
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)77.680.2073.3
SecondaryPsoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)

PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum score is 0= no disease, maximum score is 72= maximal disease.

Time frame:
Week 144 compared to Baseline of PS0014 for Cohort B
Reported as:
Number · percentage of participants
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)
percentage of participantsCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)90.085.7
SecondaryInvestigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)

The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of clear \[0\] or almost clear \[1\] with at least two category improvement from Baseline at visit timepoint.

Time frame:
Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Reported as:
Number · percentage of participants
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)
percentage of participantsCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ Total
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)76.879.0060.0
SecondaryInvestigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)

The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of 0 or 1 at Week 144.

Time frame:
Week 144 for Cohort B EP and GPP groups
Reported as:
Number · percentage of participants
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)
percentage of participantsCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)80.085.7

Adverse events

Collected over From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: BKZ 320 mg Q8W9/1,217 (0.7%)124/1,217 (10.2%)771/1,217 (63.4%)
Cohort A: BKZ 320 mg Q4W6/903 (0.7%)65/903 (7.2%)566/903 (62.7%)
Cohort A: Group A BKZ 320 mg Q8W0/226 (0%)11/226 (4.9%)97/226 (42.9%)
Cohort A: Group B BKZ 320 mg Q8W0/51 (0%)5/51 (9.8%)16/51 (31.4%)
Cohort A: Group B BKZ 320 mg Q4W/Q8W0/41 (0%)4/41 (9.8%)21/41 (51.2%)
Cohort B: PSO BKZ Total0/45 (0%)7/45 (15.6%)43/45 (95.6%)
Cohort B: EP BKZ Total0/11 (0%)5/11 (45.5%)11/11 (100%)
Cohort B: GPP BKZ Total0/10 (0%)2/10 (20%)9/10 (90%)
Most frequent serious events
Showing 10 of 218
Most frequent serious events
EventCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
Drug-induced liver injuryHepatobiliary disorders0/12170/9030/2260/510/411/450/111/10
Autoimmune hepatitisHepatobiliary disorders0/12170/9030/2260/510/410/450/111/10
Pustular psoriasisSkin and subcutaneous tissue disorders0/12170/9030/2260/510/410/450/111/10
Cardiac failure congestiveCardiac disorders1/12171/9031/2260/510/410/451/110/10
OsteoarthritisMusculoskeletal and connective tissue disorders2/12171/9030/2260/510/410/451/110/10
PleurisyRespiratory, thoracic and mediastinal disorders1/12170/9030/2260/510/410/451/110/10
Ventricular tachycardiaCardiac disorders0/12170/9030/2260/510/410/451/110/10
Oedema peripheralGeneral disorders0/12170/9030/2260/510/410/451/110/10
Pneumonia bacterialInfections and infestations0/12170/9030/2260/510/410/451/110/10
Muscular weaknessMusculoskeletal and connective tissue disorders0/12170/9030/2260/510/410/451/110/10
Most frequent other events
Showing 10 of 106
Most frequent other events
EventCohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4WCohort A: Group A BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q8WCohort A: Group B BKZ 320 mg Q4W/Q8WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ Total
NasopharyngitisInfections and infestations152/1217174/90314/2261/511/4119/457/112/10
Oral candidiasisInfections and infestations127/1217145/90313/2263/516/4111/454/112/10
EczemaSkin and subcutaneous tissue disorders30/121717/9031/2260/510/4115/453/110/10
PyrexiaGeneral disorders25/12178/9033/2260/510/4110/451/113/10
DiarrhoeaGastrointestinal disorders24/121719/9032/2260/510/417/450/112/10
Chronic gastritisGastrointestinal disorders2/12173/9030/2260/510/412/450/112/10
Alanine aminotransferase increasedInvestigations9/12175/9030/2260/510/411/450/112/10
AcneSkin and subcutaneous tissue disorders9/12179/9030/2260/510/412/450/112/10
Corona virus infectionInfections and infestations174/121718/90334/2263/518/410/450/110/10
VertigoEar and labyrinth disorders5/12177/9030/2260/510/410/452/110/10

Baseline characteristics

Baseline Characteristics refer to the Cohort A Safety Set (CA-SS) which consisted of all Cohort A study participants who received at least 1 dose of the investigational medicinal product (IMP) in this study and Cohort B Safety Set (CB-SS) which consisted of all Cohort B study participants in the Cohort B Enrolled Set (CB-ES) who received at least 1 dose of IMP in PS0014 study.

Age, Continuous
Age, Continuous(years)Cohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ TotalTotal
Mean45.3 ± 13.745.5 ± 13.245.4 ± 13.448.8 ± 11.555.3 ± 11.946.0 ± 12.545.6 ± 13.3
Age, Customized
Age, Customized(Participants)Cohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ TotalTotal
18 - <65 years349757684210101236
65 - <85 years35762310117
>= 85 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ TotalTotal
Female11822124904376
Male2666124636116977
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ TotalTotal
American Indian/Alaskan Native1100002
Asian311078451110212
Black114200017
Native Hawaiian or Other Pacific Islander2200004
White344695580001097
Other/mixed514200021
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: BKZ 320 mg Q8WCohort A: BKZ 320 mg Q4W/Q8WCohort A: BKZ 320 mg Q4WCohort B: PSO BKZ TotalCohort B: EP BKZ TotalCohort B: GPP BKZ TotalTotal
Hispanic or Latino20401100071
Not Hispanic or Latino364793594511101282
08

Study locations

189 sites
  • Ps0014 957
    Glendale, Arizona 85308, United States
  • Ps0014 946
    Phoenix, Arizona 85032, United States
  • Ps0014 910
    Bakersfield, California 93309, United States
  • Ps0014 927
    Los Angeles, California 90033, United States
  • Ps0014 919
    San Diego, California 92103, United States
  • Ps0014 955
    San Diego, California 92123, United States
  • Ps0014 943
    San Luis Obispo, California 93405, United States
  • Ps0014 967
    Santa Monica, California 90404, United States
  • Ps0014 934
    Washington D.C., District of Columbia 20016, United States
  • Ps0014 909
    Boynton Beach, Florida 33437, United States
  • Ps0014 912
    Coral Gables, Florida 33134, United States
  • Ps0014 928
    Fort Myers, Florida 33912, United States
  • Ps0014 906
    Hollywood, Florida 33021, United States
  • Ps0014 907
    Miami, Florida 33144, United States
  • Ps0014 903
    Ocala, Florida 34470, United States
  • Ps0014 921
    Ormond Beach, Florida 32174, United States
  • Ps0014 936
    Tampa, Florida 33613, United States
  • Ps0014 941
    Alpharetta, Georgia 30022, United States
  • Ps0014 954
    Skokie, Illinois 60077, United States
  • Ps0014 911
    Plainfield, Indiana 46168, United States
  • Ps0014 900
    West Des Moines, Iowa 50265, United States
  • Ps0014 905
    Overland Park, Kansas 66210, United States
  • Ps0014 962
    Owensboro, Kentucky 42301, United States
  • Ps0014 922
    Baton Rouge, Louisiana 70809, United States
  • Ps0014 944
    New Orleans, Louisiana 70115, United States
  • Ps0014 940
    Beverly, Massachusetts 01915, United States
  • Ps0014 925
    Brighton, Massachusetts 02135, United States
  • Ps0014 917
    Troy, Michigan 48084, United States
  • Ps0014 915
    Clayton, Missouri 63105, United States
  • Ps0014 958
    Omaha, Nebraska 68144, United States
  • Ps0014 901
    Portsmouth, New Hampshire 03801, United States
  • Ps0014 908
    East Windsor, New Jersey 08520, United States
  • Ps0014 956
    Verona, New Jersey 07044, United States
  • Ps0014 947
    Buffalo, New York 14221, United States
  • Ps0014 965
    Kew Gardens, New York 11415, United States
  • Ps0014 913
    New York, New York 10029-6501, United States
  • Ps0014 963
    Rochester, New York 14623, United States
  • Ps0014 961
    Rocky Mount, North Carolina 27804, United States
  • Ps0014 932
    Oklahoma City, Oklahoma 73112, United States
  • Ps0014 920
    Portland, Oregon 97210, United States
  • Ps0014 929
    Portland, Oregon 97223, United States
  • Ps0014 937
    Johnston, Rhode Island 02919, United States
  • Ps0014 945
    Greer, South Carolina 29650, United States
  • Ps0014 931
    Dallas, Texas 75231, United States
  • Ps0014 924
    Houston, Texas 77004, United States
  • Ps0014 914
    San Antonio, Texas 78213, United States
  • Ps0014 951
    Webster, Texas 77598, United States
  • Ps0014 933
    Murray, Utah 84107, United States
  • PS0014 7
    Campbelltown, Australia
  • PS0014 3
    Carlton, Australia
  • PS0014 8
    East Melbourne, Australia
  • PS0014 4
    Fremantle, Australia
  • Ps0014 10
    Kogarah, Australia
  • PS0014 6
    Kogarah, Australia
  • PS0014 5
    Phillip, Australia
  • PS0014 2
    Westmead, Australia
  • PS0014 9
    Woolloongabba, Australia
  • Ps0014 50
    Brussels, Belgium
  • Ps0014 51
    Charleroi, Belgium
  • Ps0014 52
    Liège, Belgium
  • Ps0014 658
    Ajax, Canada
  • Ps0014 659
    Calgary, Canada
  • Ps0014 672
    Edmonton, Canada
  • Ps0014 673
    Halifax, Canada
  • Ps0014 671
    Hamilton, Canada
  • Ps0014 675
    Markham, Canada
  • Ps0014 663
    Mississauga, Canada
  • Ps0014 660
    Montreal, Canada
  • Ps0014 668
    North Bay, Canada
  • Ps0014 652
    Oakville, Canada
  • Ps0014 667
    Ottawa, Canada
  • Ps0014 661
    Peterborough, Canada
  • Ps0014 665
    Québec, Canada
  • Ps0014 651
    Richmond Hill, Canada
  • Ps0014 650
    Surrey, Canada
  • Ps0014 676
    Surrey, Canada
  • Ps0014 653
    Toronto, Canada
  • Ps0014 662
    Toronto, Canada
  • Ps0014 664
    Toronto, Canada
  • Ps0014 657
    Waterloo, Canada
  • Ps0014 669
    Windsor, Canada
  • Ps0014 670
    Windsor, Canada
  • Ps0014 674
    Winnipeg, Canada
  • Ps0014 207
    Berlin, Germany
  • Ps0014 218
    Bonn, Germany
  • Ps0014 209
    Darmstadt, Germany
  • Ps0014 203
    Dresden, Germany
  • Ps0014 214
    Erlangen, Germany
  • Ps0014 208
    Frankfurt, Germany
  • Ps0014 210
    Friedrichshafen, Germany
  • Ps0014 202
    Hamburg, Germany
  • Ps0014 211
    Hamburg, Germany
  • Ps0014 220
    Hamburg, Germany
  • Ps0014 212
    Heidelberg, Germany
  • Ps0014 215
    Lübeck, Germany
  • Ps0014 213
    Mahlow, Germany
  • Ps0014 219
    Münster, Germany
  • Ps0014 205
    Osnabrück, Germany
  • Ps0014 217
    Schweinfurt, Germany
  • Ps0014 200
    Schwerin, Germany

Showing the first 100 of 189 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗
  • Thaci D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021. PubMed 36689515 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaci D. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429. PubMed 37950894 ↗
  • Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. J Am Acad Dermatol. 2024 Aug;91(2):281-289. doi: 10.1016/j.jaad.2024.03.041. Epub 2024 Apr 6. PubMed 38588819 ↗
  • Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. PubMed 39578348 ↗
  • Okubo Y, Tada Y, Takahashi H, Abe M, Yamanaka K, Tilt N, Cross N, Deherder D, Matano M, Nakagawa H. Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study. Dermatol Ther (Heidelb). 2025 Oct;15(10):2947-2966. doi: 10.1007/s13555-025-01509-9. Epub 2025 Aug 11. PubMed 40788331 ↗
  • Strober B, Boehncke WH, Krueger JG, Magnolo N, Vender R, Warren RB, Lopez Pinto JM, Kavanagh S, Hoepken B, Gisondi P. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials. Dermatol Ther (Heidelb). 2025 Dec;15(12):3633-3650. doi: 10.1007/s13555-025-01557-1. Epub 2025 Oct 8. PubMed 41060492 ↗
  • Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, Lopez Pinto JM, Wixted K, Thaci D. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatol Ther (Heidelb). 2026 Jan;16(1):585-603. doi: 10.1007/s13555-025-01595-9. Epub 2025 Dec 8. PubMed 41359217 ↗
  • Krueger JG, Cutcutache I, Lebwohl M, Gudjonsson JE, Pinter A, Langley RG, Merola J, Tada Y, Skelton A, Rastrick J, Ferecsko AS, Page M, Davies O, Lopez Pinto JM, Warham R, Shaw S, Warren RB. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. J Allergy Clin Immunol. 2026 Apr;157(4):905-916. doi: 10.1016/j.jaci.2025.12.1013. Epub 2026 Jan 22. PubMed 41580158 ↗
  • Gisondi P, Elewski B, Pinter A, Yamaguchi Y, Gooderham M, Kavanagh S, Wixted K, Cross N, Szilagyi B, Merola JF. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. J Dermatolog Treat. 2026 Dec;37(1):2637344. doi: 10.1080/09546634.2026.2637344. Epub 2026 Mar 9. PubMed 41800601 ↗
  • Merola JF, Warren RB, Thaci D, Gordon KB, Nishida E, Strober B, Conrad C, Kavanagh S, Lopez Pinto JM, Hoepken B, Gisondi P. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov;26(6):967-979. doi: 10.1007/s40257-025-00968-2. Epub 2025 Aug 31. PubMed 40886218 ↗
  • Blauvelt A, Langley RG, Lebwohl M, Strober B, Warren RB, Puig L, Morita A, Gordon KB, Fernandez-Penas P, Kavanagh S, Lopez Pinto JM, Lambert J, Hoepken B, Deherder D, Cross N, Thaci D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep;93(3):644-653. doi: 10.1016/j.jaad.2025.04.038. Epub 2025 Apr 24. PubMed 40286813 ↗
  • Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Korber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089. PubMed 36751950 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Nov 2023, 62 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 62 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2018
First posted
Jul 26, 2018
StartActual
Sep 5, 2018
Primary completionActual
Nov 14, 2023
CompletionActual
Nov 14, 2023
Results first posted
Dec 6, 2024
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03598790
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Sep 5, 2018
Primary completion
Nov 14, 2023
Completion
Nov 14, 2023
Results posted
Dec 6, 2024
Last update
Apr 15, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion